Jiangsu Huaiyu Pharmaceutical Co., Ltd.

Shandong Simcere Biopharmaceutical Co., Ltd.

Hainan Simcere Pharmaceutical Co., Ltd.

Yingying Hu

Yayuan Fu

Zhuoxiao Cao

Jinsheng Ren

Renhong Tang

Lile Liu

Hu Ge

Qing Duan

Shaoping Hu

Wei Shao

Yanyan Li

Lina Wang

Xiaodan Cao

Yan Liu

Mingming Pan

Xiaohui Shao

Yuandong Wang

Zihan Jin

Ying Gu

Siran Zhu

Xiaoxuan Lan

The present disclosure discloses IL-2 mutants and uses thereof. More specifically, the disclosure provides IL-2 mutants and corresponding fusion proteins, conjugates, nucleic acid fragments, vectors, host cells, methods for preparing the mutants or fusion proteins, IL-2 mutants or fusion proteins prepared according to the methods, pharmaceutical compositions, pharmaceutical uses, methods for treating diseases, and methods for preferentially stimulating regulatory T cells. Compared to wild-type IL-2, the IL-2 mutants of the present disclosure have higher Tm values and improved stability; alternatively, the IL-2 mutants of the present disclosure have an increased yield or changed binding activity to the IL-2Rβγ complexes compared to wild-type IL-2.

Il-2 mutant and application thereof

IL-2 mutant and application thereof

Provided are a murine or fully human monoclonal antibody targeting SEMA4D and a preparation method therefor, wherein the antibody binds to the SEMA4D antigen and has activities such as combating tumors.

SEMA4D antibody, preparation method therefor and use thereof

Growing community of inventors

Shanghai, China

Yingying Hu